MedTrace Logo

Immunogenicity and Safety Study of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine in 2-71 Months Old Healthy Infants and Toddlers (the Youngest Could be 6 Weeks Old)

NCT02736240 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2760

Last updated 2020-10-14

No results posted yet for this study

Summary

The purpose of this study is to investigate and valuate the immunogenicity and safety of the 13-valent pneumococcal polysaccharide conjugate vaccine in 2-71 months old healthy infants and toddlers (the youngest could be 6 weeks old)

Conditions

  • Diseases Caused by Streptococcus Pneumoniae Serotypes

Interventions

BIOLOGICAL

7-valent pneumococcal conjugate vaccine

BIOLOGICAL

13-valent pneumococcal polysaccharide conjugate vaccine

Sponsors & Collaborators

  • Walvax Biotechnology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Nianmin Shi · Beijing Chaoyang disease control and prevention center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
2 Months
Max Age
71 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-04-08
Primary Completion
2017-12-03
Completion
2017-12-03

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02736240 on ClinicalTrials.gov